PDE6D

PDE6D is a prenyl-binding chaperone that solubilizes farnesylated and geranylgeranylated cargo proteins by shielding their lipid moiety, enabling their cytosolic transport and correct subcellular delivery to primary cilia or the plasma membrane. Its cargo repertoire includes photoreceptor PDE6 and GRK1, the ciliary proteins INPP5E and RPGR, the oncogene KRAS, and additional prenylated proteins such as NIM1K and UBL3 (PMID:9570951, PMID:24664735, PMID:23150559, PMID:27493202, PMID:35104933, PMID:36672247). Cargo release at target membranes is triggered by ARL3-GTP, while ARL13B facilitates ciliary delivery of specific cargos such as INPP5E; loss-of-function mutations in PDE6D cause mislocalization of INPP5E from cilia and underlie Joubert syndrome (PMID:24166846, PMID:23150559). PDE6D-dependent transport of KRAS to the plasma membrane sustains RAS/ERK signaling, and pharmacological or genetic disruption of the KRAS–PDE6D interaction redirects RAS to the cytoplasm, attenuating oncogenic ERK and PI3K/AKT-RAC signaling in cancer cells (PMID:35104933, PMID:35422065, PMID:30901922).

1. 1998 Medium

   The initial question of what PDE6D does biochemically was answered: it acts as a membrane-dissociation factor that can extract the prenylated PDE6 holoenzyme from rod outer segment membranes, establishing its identity as a solubilizing chaperone for lipidated proteins.

   Evidence Biochemical fractionation of bovine rod outer segments with recombinant PDE6D

   PMID:9570951

   Open questions at the time

   • Single biochemical system (bovine rods); generality to other prenylated cargos not yet tested
   • No structural basis for prenyl recognition
2. 2012 High

   The question of whether PDE6D functions beyond photoreceptors was resolved by showing it is required for ciliary targeting of farnesylated INPP5E, with ARL13B acting as a facilitator, linking PDE6D to a broader ciliopathy network involving Joubert syndrome and nephronophthisis.

   Evidence Co-immunoprecipitation, ciliary targeting assays, and genetic epistasis in ciliopathy patient cells

   PMID:23150559

   Open questions at the time

   • Mechanism by which ARL13B promotes PDE6D-dependent ciliary delivery not molecularly defined
   • Full extent of PDE6D ciliary cargo repertoire unknown
3. 2013 High

   A pharmacological angle was opened when PDE6D was identified as the direct molecular target of anecortave acetate, and its overexpression in mouse eyes elevated intraocular pressure, revealing a potential non-canonical role in ocular physiology.

   Evidence Yeast three-hybrid screen, competitive Y3H, Co-IP, SPR, and in vivo mouse IOP measurement

   PMID:23301619

   Open questions at the time

   • Which prenylated cargo mediates the IOP phenotype is unknown
   • Mechanism linking PDE6D to aqueous humor dynamics not established
4. 2014 High

   Causative disease mutations were defined: a PDE6D splice-site mutation reduces binding to both INPP5E and ARL3-GTP, establishing ARL3-GTP as the cargo-release factor for PDE6D and providing a molecular mechanism for Joubert syndrome pathogenesis.

   Evidence Exome sequencing, Co-IP with mutant PDE6D, immunofluorescence in patient fibroblasts, zebrafish pde6d knockdown rescue

   PMID:24166846

   Open questions at the time

   • Whether residual PDE6D activity modifies disease severity not tested
   • No structural model of how the splice mutation disrupts ARL3 binding
5. 2014 High

   Genetic epistasis in mice demonstrated that PDE6D is essential for trafficking both PDE6 and GRK1 to photoreceptor outer segments, and revealed interdependence with the acylated-protein chaperone UNC119, showing that prenylated and myristoylated trafficking pathways are coupled.

   Evidence Pde6d knockout and Pde6d/Unc119 double knockout mice, ERG recordings, immunofluorescence

   PMID:24664735

   Open questions at the time

   • Molecular basis of UNC119–PDE6D crosstalk not defined
   • Whether the double-KO rescue extends to rods not shown
6. 2015 Medium

   The determinants of cargo specificity were clarified: PDE6D binds the C-terminal prenyl moiety of RPGR, with the amino acid adjacent to the prenylation CAAX motif dictating selectivity, expanding the cargo list to include a key retinal ciliopathy protein.

   Evidence Co-IP in mammalian cells with prenylation-site mutants and domain mapping

   PMID:26553938 PMID:27493202

   Open questions at the time

   • No structural data for RPGR–PDE6D complex
   • Single-lab finding without independent replication of the specificity determinant
7. 2019 Medium

   Functional consequences of PDE6D for oncogenic signaling were established: PDE6D depletion blocks KRAS plasma-membrane localization, reduces ERK activation, and suppresses proliferation in hepatocellular carcinoma cells, positioning PDE6D as an enabler of RAS pathway output.

   Evidence siRNA knockdown, overexpression, cell proliferation/migration assays, ERK phosphorylation western blot in HCC cells

   PMID:30901922

   Open questions at the time

   • Single cancer type; breadth across RAS-driven cancers not tested
   • No in vivo tumor model
8. 2022 High

   Structural and chemical biology approaches validated PDE6D as a druggable node: co-crystal structures of fragments at the KRAS–PDE6D interface were obtained, and stabilizing the RAS–PDE6D complex by affinity-enhancing RAS mutations redirected RAS to the cytoplasm and cilium, proving that modulating complex lifetime controls RAS signaling output.

   Evidence RAS affinity-engineered mutants, SPR fragment screening, co-crystal structures, cell-based RAS localization and ERK assays

   PMID:35104933

   Open questions at the time

   • No drug-like inhibitor with in vivo efficacy reported from these fragments
   • Effect on non-KRAS prenylated cargos not assessed
9. 2022 Medium

   The signaling reach of PDE6D-mediated RAS transport was extended to RAC activation through PI3K/AKT: chemical inhibition of PDE6D with DW0254 blocked both RAS membrane localization and downstream RAC activation in leukemia cells.

   Evidence Chemical proteomics, biophysical binding assays, RAS/RAC localization, PI3K/AKT inhibitor epistasis in leukemia cells

   PMID:35422065

   Open questions at the time

   • DW0254 selectivity for PDE6D over UNC119 not fully characterized
   • In vivo antileukemic activity not demonstrated
10. 2023 Medium

    The prenylated cargo repertoire of PDE6D was substantially broadened by affinity proteomics, identifying NIM1K and UBL3 as novel ciliary cargos, with UBL3 linking PDE6D to extracellular vesicle biogenesis and ciliogenesis.

    Evidence Affinity proteomics pulldown of PDE6D interactors, immunofluorescence with prenylation mutants, UBL3 interactome analysis

    PMID:36672247

    Open questions at the time

    • Functional consequence of NIM1K or UBL3 mislocalization not tested
    • Single-lab proteomics without independent validation of novel cargos
11. 2024 Medium

    Post-translational regulation of the KRAS–PDE6D interaction was uncovered: PKG2-mediated phosphorylation of K-Ras Ser181 weakens PDE6D binding, and combining a PDE6D inhibitor with PKG2 activation synergistically blocks KRAS–PDE6D association and cancer cell proliferation.

    Evidence Phosphomimetic mutant binding assays, pharmacological combination of Deltaflexin3 and Sildenafil, proliferation assays

    PMID:38758695

    Open questions at the time

    • Ser181 phosphorylation not confirmed with endogenous PKG2 signaling
    • Synergy not tested in vivo or in primary patient samples

• Key unresolved questions include: how PDE6D achieves cargo selectivity among the many prenylated proteins in the cell; the precise membrane-proximal mechanism by which ARL3-GTP releases cargo at target compartments; and whether therapeutic modulation of PDE6D can selectively disrupt oncogenic RAS signaling without impairing ciliary and photoreceptor functions.
• No complete structural model of the ARL3-GTP/PDE6D/cargo ternary release complex
• In vivo therapeutic window for PDE6D inhibition not established
• Selectivity mechanism for individual prenylated cargos not resolved